1. |
吉爱军, 唐金海.乳腺癌术后患者Cyclin A1、A2、D1、E1表达及其临床意义[J].南京医科大学学报:自然科学版, 2010, 30(9):1290-1294.
|
2. |
Kohlberger PD, Breitenecker F, Kaider A, et al.Modified true-color computer-assisted image analysis versus subjective scoringof estrogen receptor expression in breast cancer:a comparison[J].Anticancer Res, 1999, 19(3B):2189-2193.
|
3. |
张怡, 王娟娟, 郭宇, 等.microRNA沉默SMYD3基因对乳腺癌细胞Wnt/β-Catenin通路及c-Myc基因影响的研究[J].医学研究杂志, 2013, 42(6):171-173.
|
4. |
张荣君, 章佳新, 扶德元, 等.SOX7、β-catenin和cyclin D1蛋白在浸润性乳腺癌组织中的表达及临床意义[J].国际外科学杂志, 2013, 40(9):599-604.
|
5. |
吴珏堃.β-catenin与cyclin D1在乳腺癌中的表达及与其他临床病理指标的相关性分析[J].实用医学杂志, 2011, 27(9):1613-1616.
|
6. |
师杰, 梁智勇, 刘彤华.Cyclin D1在乳腺浸润性小叶癌的表达及其意义[J].协和医学杂志, 2012, 3(1):8-12.
|
7. |
疏楠, 李连宏, 孙志刚, 等.P16、CDK4、cyclin D1在乳腺癌中的表达及临床意义[J].大连医科大学学报, 2009, 31(4):255-259.
|
8. |
罗洁, 陈俞霖, 许辉.β-catenin, cyclin D1和ERα在乳腺癌组织中的表达[J].实用预防医学, 2010, 17(8):1502-1504.
|
9. |
Zwijsen RM, Wientjens E, Klompmaker R, et al.CDK-indepen-dent activation of estrogen receptor by cyclin D1[J].Cell, 1997, 88(3):405-415.
|
10. |
Umekita Y, Ohi Y, Sagara Y, et al.Overexpression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients[J].Int J Cancer, 2002, 98(3):415-418.
|
11. |
赵俊玲, 杨金巧, 赖毅.Cyclin D1基因扩增及其蛋白表达在乳腺癌中的意义[J].中国普外基础与临床杂志, 2000, 7(3):147-149.
|
12. |
Sutherland RL, Prall OW, Alle KM, et al.Cyclin dependent kinases as downstream targets of oestrogen action:potential prognostic indicators and therapeutic targets[J].Endorine Related Cancer, 1997, 4:357-370.
|
13. |
Khalil S, Tan GA, Giri DD, et al.Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues:relationship to HER2/neu expression in human and mouse[J].PLoS One, 2012, 7(3):e33421.
|
14. |
Geyer FC, Lacroix-Triki M, Savage K, et al.β-Catenin pathway activation in breast cancer is associated with triple-negative pheno-type but not with CTNNB1 mutation[J].Mod Pathol, 2011, 24(2):209-231.
|
15. |
夏红强, 何建蓉.Ki-67、EGFR、HER-2和p53在乳腺癌中的表达及其相关性[J].临床肿瘤学杂志, 2011, 16(2):139-143.
|
16. |
何艳蛟, 乔超, 刘朝霞, 等.乳腺癌中β-catenin, cyclin D1, c-myc表达及意义[J].首都医科大学学报, 2011, 32(4):549-552.
|
17. |
Carey LA, Perou CM, Livasy CA, et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J].JAMA, 2006, 295(21):2492-2502.
|
18. |
张英军, 吴君心, 侯如蓉.乳腺癌的分子分型[J].实用癌症杂志, 2012, 27(1):98-100.
|
19. |
Su YH, Zheng Y, Zheng W, et al.Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women:a population-based cohort study[J].BMC Cancer, 2011, 11:292.
|
20. |
董晓, 房新志, 柴敏秀, 等.β-Catenin和Cyclin D1在乳腺癌中的表达及意义[J].新疆医科大学学报, 2008, 31(5):541-547.
|
21. |
高鹏, 周庚寅, 刘文君, 等.乳腺癌中细胞周期素D1基因改变和转录异常对其蛋白表达的影响[J].中国现代普通外科进展, 2004, 7(1):31-34.
|
22. |
Hwang TS, Han HS, Hong YC, et al.Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients[J].Pathol Int, 2003, 53(2):74-80.
|
23. |
陈晓曦, 陈吉彩, 程骏, 等.cyclin D1在乳腺癌中的表达及意义[J].山东医药, 2006, 46(34):64-65.
|
24. |
Gillett C, Smith P, Gregory W, et al.Cyclin D1 and prognosis in human breast cancer[J].Int J Cancer, 1996, 69(2):92-99.
|
25. |
Pelosio P, Barbareschi M, Bonoldi E, et al.Clinical significance of cyclin D1 expression in patients with node-positive breast carci-noma treated with adjuvant therapy[J].Ann Oncol, 1996, 7(7):695-703.
|
26. |
张云伟, 贾宗良.乳腺癌改良根治术后复发和转移因素分析[J].中国普外基础与临床杂志, 2012, 19(9):988-990.
|